|
humans |
28 |
|
male |
23 |
|
female |
22 |
|
apoptosis |
20 |
|
covid-19 |
20 |
|
adult |
19 |
|
middle aged |
17 |
|
aged |
14 |
|
cells, cultured |
14 |
|
traditional chinese medicine |
14 |
|
chronic kidney disease |
13 |
|
proteinuria |
13 |
|
kidney transplantation |
12 |
|
renal transplantation |
12 |
|
alzheimer's disease |
11 |
|
beta-amyloid |
11 |
|
chinese |
11 |
|
epidemiology |
10 |
|
outcomes |
10 |
|
pasc |
10 |
|
post-acute sequelae of sars-cov-2 |
10 |
|
sars-cov-2 |
10 |
|
treatment outcome |
10 |
|
base sequence |
9 |
|
diabetic nephropathy |
9 |
|
genotype |
9 |
|
hepatitis b |
9 |
|
membranous nephropathy |
9 |
|
adolescent |
8 |
|
appswe/ps1de9 |
8 |
|
aquaporin 9 |
8 |
|
biopsy |
8 |
|
creatinine - blood |
8 |
|
diabetes mellitus |
8 |
|
dialysis |
8 |
|
glomerular filtration rate |
8 |
|
hepatitis b vaccination |
8 |
|
iga nephropathy |
8 |
|
immunosuppression - adverse effects |
8 |
|
intradermal |
8 |
|
peritoneal dialysis |
8 |
|
peritoneal dialysis, continuous ambulatory - adverse effects |
8 |
|
risk factors |
8 |
|
rna, messenger - genetics - metabolism |
8 |
|
sodium |
8 |
|
tlr7 agonist |
8 |
|
transplantation, homologous |
8 |
|
5-fluorouracil |
7 |
|
bone marrow transplantation |
7 |
|
clinical trial |
7 |
|
dna primers - genetics |
7 |
|
drug therapy, combination |
7 |
|
follow-up studies |
7 |
|
glucose - pharmacology |
7 |
|
immunoglobulin a - metabolism |
7 |
|
immunosuppression |
7 |
|
immunosuppressive agents - therapeutic use |
7 |
|
kidney - pathology |
7 |
|
kidney transplantation - adverse effects |
7 |
|
nephrotic syndrome |
7 |
|
nf-κb |
7 |
|
peritoneal dialysis - methods |
7 |
|
peritoneal dialysis, continuous ambulatory |
7 |
|
post-transplantation lymphoproliferative disease |
7 |
|
pragmatic |
7 |
|
prospective studies |
7 |
|
solid organ transplantation |
7 |
|
tnf-α |
7 |
|
albuminuria |
6 |
|
antioxidant activity |
6 |
|
antioxidants - analysis - metabolism |
6 |
|
aquaporin 1 |
6 |
|
aquaporin-5 |
6 |
|
arctium - chemistry - genetics - metabolism |
6 |
|
burdock |
6 |
|
caffeoylquinic acids |
6 |
|
capd |
6 |
|
case-control studies |
6 |
|
chemokine |
6 |
|
chinese medicine |
6 |
|
chronic allograft nephropathy |
6 |
|
chronic obstructive pulmonary disease |
6 |
|
clinical trials |
6 |
|
colorectal cancer |
6 |
|
complementary medicine |
6 |
|
dendrobium officinale polysaccharides |
6 |
|
diabetes & endocrinology |
6 |
|
diabetic nephropathy & vascular disease |
6 |
|
diet therapy |
6 |
|
dna primers |
6 |
|
fever - etiology |
6 |
|
gene expression |
6 |
|
gene expression - drug effects |
6 |
|
gene expression regulation - immunology |
6 |
|
hong kong |
6 |
|
ht-29 cells |
6 |
|
immunosuppressive agents |
6 |
|
intestinal mucositis |
6 |
|
kidney failure, chronic - complications - therapy |
6 |
|
kinetics |
6 |
|
lc-ms |
6 |
|
lignans |
6 |
|
lignans - analysis - metabolism |
6 |
|
maldi-qit-tof ms |
6 |
|
medical sciences |
6 |
|
mucin-5ac |
6 |
|
mycophenolate mofetil |
6 |
|
nephrology |
6 |
|
nephropathy |
6 |
|
outcome |
6 |
|
pedigree |
6 |
|
peritoneal dialysis - adverse effects |
6 |
|
peritoneum - cytology |
6 |
|
phytochemical |
6 |
|
plant extracts - analysis - metabolism |
6 |
|
plant roots - chemistry - genetics - metabolism |
6 |
|
polyoma bk virus |
6 |
|
pomegranate peel ellagitannins |
6 |
|
proteinuria - etiology |
6 |
|
quantitative pcr |
6 |
|
quinic acid - analogs & derivatives - analysis - metabolism |
6 |
|
reactive oxygen species - metabolism |
6 |
|
roots |
6 |
|
seeds |
6 |
|
seeds - chemistry - genetics - metabolism |
6 |
|
severity of illness index |
6 |
|
survival |
6 |
|
time factors |
6 |
|
transferrin |
6 |
|
type 2 diabetes mellitus |
6 |
|
up-regulation |
6 |
|
up-regulation - drug effects |
6 |
|
urology and nephrology |
6 |
|
1-phosphatidylinositol 3-kinase - antagonists & inhibitors - metabolism |
5 |
|
a-253 |
5 |
|
active components |
5 |
|
adriamycin nephropathy |
5 |
|
animals |
5 |
|
anti-bacterial agents - therapeutic use |
5 |
|
aquaporin 3 |
5 |
|
aquaporin 5 |
5 |
|
azathioprine - therapeutic use |
5 |
|
bioavailability |
5 |
|
blood pressure |
5 |
|
breast cancer |
5 |
|
cardiovascular diseases - mortality |
5 |
|
catheters, indwelling |
5 |
|
cell survival - drug effects |
5 |
|
chronic disease |
5 |
|
complement |
5 |
|
complication |
5 |
|
culture media, conditioned |
5 |
|
cyclophosphamide |
5 |
|
dendrobium officinale |
5 |
|
diabetes |
5 |
|
diagnosis, differential |
5 |
|
dialysis initiation |
5 |
|
direct renin inhibitor |
5 |
|
dose-response relationship, drug |
5 |
|
edible plants |
5 |
|
fibrosis |
5 |
|
ficus virens |
5 |
|
glucose |
5 |
|
glucose degradation products |
5 |
|
health preference |
5 |
|
health-related quality of life |
5 |
|
heart disease |
5 |
|
herbal interactions |
5 |
|
hypernatraemia |
5 |
|
immunoblotting |
5 |
|
induced pluripotent stem cells |
5 |
|
interleukin-8 - biosynthesis - genetics |
5 |
|
intestinal absorption |
5 |
|
kaplan-meier estimate |
5 |
|
kidney |
5 |
|
kidney diseases - pathology |
5 |
|
kidney failure, chronic - complications - mortality - physiopathology - therapy |
5 |
|
kidney failure, chronic - therapy |
5 |
|
kidney tubules, proximal - drug effects - immunology - injuries - metabolism |
5 |
|
kidney tubules, proximal - metabolism |
5 |
|
living donors |
5 |
|
lymph node metastatic carcinoma |
5 |
|
membranous lupus nephritis |
5 |
|
mesenchymal stem cells |
5 |
|
metastasis |
5 |
|
microvascular complications |
5 |
|
mucositis |
5 |
|
mycophenolic acid - adverse effects - analogs & derivatives - therapeutic use |
5 |
|
mycophenolic acid - analogs & derivatives - therapeutic use |
5 |
|
nf-kappa b - antagonists & inhibitors - metabolism |
5 |
|
non-small cell lung cancer |
5 |
|
peritoneal mesothelial cells |
5 |
|
peritoneum |
5 |
|
peritonitis |
5 |
|
polymerase chain reaction |
5 |
|
polymeric iga |
5 |
|
polysaccharides |
5 |
|
prednisolone - adverse effects - therapeutic use |
5 |
|
prednisolone - therapeutic use |
5 |
|
prevalence |
5 |
|
primary carcinoma |
5 |
|
proanthocyanidins |
5 |
|
proteinuria - drug therapy |
5 |
|
proteinuria - drug therapy - etiology |
5 |
|
quality control |
5 |
|
remission |
5 |
|
renal insufficiency - etiology |
5 |
|
retrospective studies |
5 |
|
stroke |
5 |
|
survival rate |
5 |
|
tacrolimus |
5 |
|
therapeutic potential |
5 |
|
tomography, x-ray computed |
5 |
|
treatment refusal |
5 |
|
uraemic symptoms |
5 |
|
uremia - etiology |
5 |
|
vascular endothelial growth factor |
5 |
|
water channel |
5 |
|
zonula occludens protein 1 |
5 |
|
α-secretases |
5 |
|
β-secretases |
5 |
|
abdominal pain - microbiology |
4 |
|
advanced glycation end-products |
4 |
|
akt |
4 |
|
albumin |
4 |
|
alopecia - chemically induced |
4 |
|
alpha-fetoproteins - analysis |
4 |
|
alpha-galactosidase - genetics |
4 |
|
angiography - adverse effects - economics - methods |
4 |
|
angioplasty, balloon |
4 |
|
angiotensin-converting enzyme inhibitors - therapeutic use |
4 |
|
anionic charge |
4 |
|
anti-diabetic agents |
4 |
|
anti-hypertensive |
4 |
|
anti-inflammatory agents - administration & dosage - adverse effects |
4 |
|
antibodies - pharmacology |
4 |
|
antigens, cd - analysis |
4 |
|
antigens, differentiation, myelomonocytic - analysis |
4 |
|
antilymphocyte serum - therapeutic use |
4 |
|
aqp-3 |
4 |
|
aquaporin 1 (aqp1) |
4 |
|
aquaporin 3 (aqp3) |
4 |
|
aquaporins - analysis - genetics |
4 |
|
aquaporins - genetics - metabolism |
4 |
|
asian continental ancestry group - genetics |
4 |
|
at1r |
4 |
|
azathioprine |
4 |
|
azathioprine - administration & dosage - adverse effects |
4 |
|
binding sites |
4 |
|
biological markers - metabolism |
4 |
|
bk virus - isolation & purification - physiology |
4 |
|
blood group antigens |
4 |
|
blood pressure - drug effects |
4 |
|
bradykinin |
4 |
|
bradykinin - physiology |
4 |
|
cadaver |
4 |
|
carbon radioisotopes - diagnostic use |
4 |
|
carcinoma, hepatocellular - diagnosis - etiology - surgery |
4 |
|
carrier state |
4 |
|
catheterization, central venous - instrumentation |
4 |
|
cell injury |
4 |
|
cell membrane permeability - drug effects |
4 |
|
cell proliferation - drug effects |
4 |
|
cell survival |
4 |
|
charge dependent iga binding |
4 |
|
chemokines |
4 |
|
chemokines - genetics |
4 |
|
chemotaxis |
4 |
|
china |
4 |
|
chromatography, ion exchange |
4 |
|
chromosome banding |
4 |
|
chromosomes, human, x |
4 |
|
chronic renal disease |
4 |
|
chrysotoxine |
4 |
|
ciclosporin a |
4 |
|
circadian rhythm |
4 |
|
cohort studies |
4 |
|
collagen type i - genetics |
4 |
|
complement c3 - analysis |
4 |
|
computer systems |
4 |
|
connective tissue growth factor - genetics - metabolism |
4 |
|
continuous ambulatory peritoneal dialysis |
4 |
|
conventional arteriogram |
4 |
|
cost |
4 |
|
creatinine - metabolism |
4 |
|
cross-over studies |
4 |
|
ct angiogram |
4 |
|
ctgf/ccn2 |
4 |
|
culture media, conditioned - pharmacology |
4 |
|
cyclophosphamide - administration & dosage - adverse effects |
4 |
|
cyclosporine - blood - therapeutic use |
4 |
|
cyclosporine - therapeutic use |
4 |
|
cytokines - genetics - metabolism |
4 |
|
cytokines - metabolism |
4 |
|
cytomegalovirus infections - epidemiology |
4 |
|
cytoskeletal proteins - genetics |
4 |
|
debridement |
4 |
|
deposits of iga |
4 |
|
diabetes mellitus, experimental - immunology - metabolism |
4 |
|
diabetic nephropathies - immunology - metabolism |
4 |
|
diabetic nephropathies - pathology - physiopathology |
4 |
|
dialysis solutions - toxicity |
4 |
|
differentiation |
4 |
|
diuretics, osmotic - pharmacology |
4 |
|
dna, viral - analysis - blood - urine |
4 |
|
electric impedance |
4 |
|
electrophysiology |
4 |
|
endoplasmic reticulum stress |
4 |
|
endothelial cells - drug effects - metabolism - pathology |
4 |
|
enterococcus peritonitis |
4 |
|
epithelial cells - chemistry - cytology - physiology |
4 |
|
epithelial cells - cytology |
4 |
|
epithelial cells - drug effects - metabolism |
4 |
|
epithelial cells - drug effects - metabolism - pathology |
4 |
|
epithelial cells - immunology - metabolism |
4 |
|
epithelial cells - physiology |
4 |
|
exons |
4 |
|
expectation |
4 |
|
fabry disease - enzymology - genetics - physiopathology |
4 |
|
fabry's disease |
4 |
|
fasciitis, necrotizing - diagnosis - etiology - therapy |
4 |
|
fibroblasts - drug effects - metabolism - pathology |
4 |
|
focal segmental glomerulosclerosis |
4 |
|
general practice |
4 |
|
genetic mutation |
4 |
|
glomerular mesangial cell |
4 |
|
glomerular mesangium - cytology - immunology - metabolism |
4 |
|
glomerular mesangium - metabolism - pathology |
4 |
|
glomerulonephritis |
4 |
|
glomerulonephritis, iga - genetics - immunology - pathology |
4 |
|
glomerulonephritis, iga - metabolism |
4 |
|
glomerulonephritis, iga - metabolism - pathology |
4 |
|
glomerulonephritis, membranous - drug therapy |
4 |
|
glucose - physiology |
4 |
|
glycerol - pharmacokinetics |
4 |
|
glycosylation |
4 |
|
graft rejection |
4 |
|
graft rejection - blood - prevention & control |
4 |
|
gram-positive bacterial infections - drug therapy - etiology |
4 |
|
hemodialysis |
4 |
|
hepatitis |
4 |
|
hepatitis - diagnosis - etiology |
4 |
|
hepatitis b infection |
4 |
|
hepatocellular carcinoma |
4 |
|
hepatocyte growth factor |
4 |
|
herpes zoster |
4 |
|
herpes zoster - chemically induced |
4 |
|
heterozygote detection |
4 |
|
high glucose |
4 |
|
hmgb1 protein - metabolism |
4 |
|
hong kong - epidemiology |
4 |
|
hsp70 heat-shock proteins - metabolism |
4 |
|
human peritoneal mesothelial cell |
4 |
|
hyperglycemia - physiopathology |
4 |
|
hypertension |
4 |
|
i-kappa b kinase - metabolism |
4 |
|
iga1 |
4 |
|
igan |
4 |
|
immunoglobulin a (iga) nephropathy |
4 |
|
immunoglobulin a nephropathy |
4 |
|
immunosuppressive agents - administration & dosage - adverse effects |
4 |
|
immunosuppressive agents - adverse effects - therapeutic use |
4 |
|
immunosuppressive agents - blood - therapeutic use |
4 |
|
influenza |
4 |
|
insulin-independent |
4 |
|
integrative medicine |
4 |
|
interleukin-6 - genetics |
4 |
|
internal medicine |
4 |
|
interstitial fibrosis |
4 |
|
invasive pneumococcal disease |
4 |
|
ivig |
4 |
|
jak-stat |
4 |
|
kallirein |
4 |
|
kidney cortex - metabolism |
4 |
|
kidney diseases - blood - drug therapy - therapy |
4 |
|
kidney diseases - diagnosis - etiology - pathology |
4 |
|
kidney failure, chronic - complications - metabolism - pathology - therapy |
4 |
|
kidney failure, chronic - pathology - therapy |
4 |
|
kidney mesangial cells |
4 |
|
kidney neoplasms - pathology |
4 |
|
kidney transplantation - immunology - physiology |
4 |
|
kidney tubules, proximal - cytology - immunology - metabolism |
4 |
|
kidney tubules, proximal - pathology - physiopathology |
4 |
|
lectins - metabolism |
4 |
|
leptin |
4 |
|
leptin - physiology |
4 |
|
leptin receptor |
4 |
|
lipotoxicity |
4 |
|
liver neoplasms - diagnosis - etiology - surgery |
4 |
|
living kidney donor |
4 |
|
lupus nephritis |
4 |
|
lupus nephritis - complications - drug therapy - virology |
4 |
|
lupus nephritis - drug therapy |
4 |
|
lymphoma - pathology |
4 |
|
lymphotoxin-alpha - metabolism |
4 |
|
macrophages - physiology |
4 |
|
magnetic resonance imaging |
4 |
|
mannitol - pharmacology |
4 |
|
matrix metalloproteinase 9 - genetics |
4 |
|
mechanism |
4 |
|
medicinal plants |
4 |
|
membrane proteins - genetics |
4 |
|
membranous glomerulonephritis |
4 |
|
mesangial cell |
4 |
|
mesangial cells - immunology |
4 |
|
mesothelial cell |
4 |
|
mice |
4 |
|
mice, inbred c57bl |
4 |
|
mice, knockout |
4 |
|
minimization |
4 |
|
mitochondrial dysfunctions |
4 |
|
monocytes - physiology |
4 |
|
mortality |
4 |
|
mpp + |
4 |
|
mycophenolate |
4 |
|
necrotizing fasciitis |
4 |
|
nephritis, interstitial - immunology - physiopathology |
4 |
|
nephrotic syndrome - complications - drug therapy |
4 |
|
nephrotic syndrome - drug therapy |
4 |
|
nf-kappa b - metabolism |
4 |
|
nfκb |
4 |
|
non-surgical periodontal therapy |
4 |
|
notch1 |
4 |
|
osmolality |
4 |
|
osteonectin - genetics |
4 |
|
periodontitis |
4 |
|
peritoneal cavity - cytology |
4 |
|
peritoneal dialysis - adverse effects - methods |
4 |
|
peritoneal dialysis peritoneal mesothelial cells |
4 |
|
peritoneum - drug effects - metabolism |
4 |
|
peritoneum - drug effects - metabolism - pathology |
4 |
|
peritonitis - drug therapy - microbiology |
4 |
|
platelet-derived growth factor - immunology - secretion |
4 |
|
podocytes |
4 |
|
podocytes - immunology - metabolism - pathology |
4 |
|
polycation |
4 |
|
polymerase chain reaction - methods |
4 |
|
polymers - metabolism |
4 |
|
polyomavirus infections - blood - urine - virology |
4 |
|
polysomnography |
4 |
|
portal vein - radiography |
4 |
|
postoperative complications - blood - urine - virology |
4 |
|
postoperative complications - virology |
4 |
|
postoperative period |
4 |
|
prednisone - administration & dosage - adverse effects |
4 |
|
prognosis |
4 |
|
progressive outer retinal necrosis |
4 |
|
prorenin receptor |
4 |
|
protein kinase c - metabolism |
4 |
|
proteinuria - immunology - metabolism |
4 |
|
qualitative |
4 |
|
quality of life |
4 |
|
receptor |
4 |
|
receptor-like protein tyrosine phosphatases, class 3 - genetics |
4 |
|
receptors, cell surface - biosynthesis |
4 |
|
receptors, leptin |
4 |
|
regenerative medicine |
4 |
|
regression analysis |
4 |
|
remission induction - methods |
4 |
|
renal dialysis - instrumentation - methods |
4 |
|
renal failure |
4 |
|
renal function |
4 |
|
renal transplant |
4 |
|
renin inhibitor |
4 |
|
respiratory system - pathology |
4 |
|
respiratory tract infections - chemically induced |
4 |
|
reverse transcriptase polymerase chain reaction |
4 |
|
rna, messenger - biosynthesis |
4 |
|
rotenone |
4 |
|
secondary syphilis |
4 |
|
self-renewal |
4 |
|
serum albumin |
4 |
|
serum albumin - analysis |
4 |
|
serum albumin - pharmacology |
4 |
|
shock, septic - diagnosis - etiology - therapy |
4 |
|
sialylation |
4 |
|
sleep apnea |
4 |
|
sleep apnea syndromes - etiology - prevention & control |
4 |
|
slit diaphragm |
4 |
|
sodium–glucose co-transporter type 2 inhibitors |
4 |
|
stem cell |
4 |
|
streptococcus pyogenes |
4 |
|
syphilis - complications - diagnosis - pathology |
4 |
|
syphilis, cutaneous - complications - diagnosis |
4 |
|
systematic review |
4 |
|
tacrolimus - adverse effects - therapeutic use |
4 |
|
tacrolimus - blood - therapeutic use |
4 |
|
tacrolimus - therapeutic use |
4 |
|
tacrolimus conversion |
4 |
|
tgf-β |
4 |
|
three pore model |
4 |
|
tissue donors |
4 |
|
toll-like receptor 2 - metabolism |
4 |
|
toll-like receptor 4 - genetics - metabolism |
4 |
|
tomography, x-ray computed - adverse effects - economics - methods |
4 |
|
transferrin - pharmacology |
4 |
|
transforming growth factor beta - biosynthesis |
4 |
|
transforming growth factor beta - genetics - metabolism |
4 |
|
transforming growth factor-β |
4 |
|
tubuloglomerular cross talk |
4 |
|
tubulointerstitial injury |
4 |
|
tumor necrosis factor-alpha - metabolism |
4 |
|
tumor necrosis factor-α |
4 |
|
tumor virus infections - blood - urine - virology |
4 |
|
tumour necrosis factor-α |
4 |
|
ultrasmall pores |
4 |
|
up-regulation - drug effects - immunology |
4 |
|
urea - metabolism |
4 |
|
uremia - etiology - metabolism - pathology - therapy |
4 |
|
urinary tract infections - chemically induced |
4 |
|
urine - virology |
4 |
|
varicella zoster virus |
4 |
|
vascular anomalies |
4 |
|
vascular endothelial growth factor a - genetics - metabolism |
4 |
|
vascular neoplasms - pathology |
4 |
|
vegf |
4 |
|
viral load |
4 |
|
viremia - virology |
4 |
|
virus activation |
4 |
|
wedge resection |
4 |
|
weight loss |
4 |
|
α-galactosidase a |
4 |
|
γ-iga |
4 |
|
2-aminopurine - analogs & derivatives - therapeutic use |
3 |
|
acacb |
3 |
|
ace inhibitors |
3 |
|
acetyl-coa carboxylase - genetics |
3 |
|
acetylgalactosamine - analysis |
3 |
|
actinomycetales infections - drug therapy - microbiology - radiography |
3 |
|
acute disease |
3 |
|
acute kidney injury |
3 |
|
acute kidney injury - immunology - pathology |
3 |
|
acute-phase proteins - genetics - immunology - metabolism |
3 |
|
adipocyte |
3 |
|
adipocytes |
3 |
|
adipokines |
3 |
|
adrenal cortex hormones - therapeutic use |
3 |
|
advanced glycation end-product |
3 |
|
age distribution |
3 |
|
age of onset |
3 |
|
aged, 80 and over |
3 |
|
alanine transaminase - metabolism |
3 |
|
albumins |
3 |
|
alcaligenes |
3 |
|
alcaligenes xylosoxidans |
3 |
|
aldosterone - pharmacology |
3 |
|
allograft |
3 |
|
ambulatory care |
3 |
|
analysis of variance |
3 |
|
angiography |
3 |
|
angiography - economics - methods |
3 |
|
angiotensin ii |
3 |
|
angiotensin ii - metabolism |
3 |
|
angiotensin ii - pharmacology - secretion |
3 |
|
angiotensin ii subtype-1 receptor |
3 |
|
angiotensin ii subtype-2 receptor |
3 |
|
angiotensin ii type 1 receptor |
3 |
|
angiotensin ii type 1 receptor blockers - pharmacology |
3 |
|
angiotensin ii type 1 receptor blockers - pharmacology - therapeutic use |
3 |
|
angiotensin receptor antagonists |
3 |
|
angiotensin receptor blocker |
3 |
|
angiotensin receptor blocker (arb) |
3 |
|
angiotensin-converting enzyme inhibitor (acei) |
3 |
|
angiotensin-converting enzyme inhibitors - pharmacology - therapeutic use |
3 |
|
animal model |
3 |
|
anionic iga |
3 |
|
anions |
3 |
|
anti-bacterial agents - adverse effects - pharmacokinetics |
3 |
|
anti-inflammatory agents - pharmacology |
3 |
|
antibodies - analysis - immunology |
3 |
|
antibodies, antineutrophil cytoplasmic - analysis - immunology |
3 |
|
antibodies, monoclonal |
3 |
|
antibody specificity |
3 |
|
antigen-antibody complex - metabolism |
3 |
|
antihypertensive agents - therapeutic use |
3 |
|
antitubercular agents - therapeutic use |
3 |
|
antiviral agents - administration & dosage - adverse effects - therapeutic use |
3 |
|
anuria - mortality - physiopathology - therapy |
3 |
|
apoproteins - pharmacology |
3 |
|
apoptosis - drug effects |
3 |
|
apoptosis - physiology |
3 |
|
aquaporin 2 |
3 |
|
aquaporin 4 |
3 |
|
aquaporins |
3 |
|
aquaporins - genetics - immunology - metabolism |
3 |
|
ascites - etiology - therapy |
3 |
|
asian continental ancestry group |
3 |
|
autoantibodies |
3 |
|
b2-kinin receptor blockade |
3 |
|
basement membrane - chemistry - immunology |
3 |
|
beta-catenin |
3 |
|
beta-lactamases - biosynthesis |
3 |
|
binding, competitive |
3 |
|
biological transport, active |
3 |
|
biomarker |
3 |
|
biopsy, needle - adverse effects - methods |
3 |
|
bk virus - genetics - isolation and purification |
3 |
|
bmp-7 |
3 |
|
bone morphogenetic protein 7 - physiology |
3 |
|
cadherins - metabolism |
3 |
|
captopril - administration & dosage |
3 |
|
carboxymethyllysine albumin |
3 |
|
carcinoma, hepatocellular - diagnosis - pathology |
3 |
|
cardiovascular event |
3 |
|
cardiovascular morbidity |
3 |
|
cations |
3 |
|
cd25 |
3 |
|
cell communication |
3 |
|
cell communication - physiology |
3 |
|
cell culture techniques - methods |
3 |
|
cell line |
3 |
|
cell line, tumor - metabolism |
3 |
|
cell movement |
3 |
|
cell proliferation |
3 |
|
cell viability |
3 |
|
cells, cultured - cytology |
3 |
|
cells, cultured - metabolism - pathology |
3 |
|
cephalosporin |
3 |
|
chemokine ccl2 - biosynthesis - genetics |
3 |
|
chemokine ccl2 - genetics - metabolism |
3 |
|
chemokine ccl2 - metabolism |
3 |
|
chemokine ccl5 |
3 |
|
chemokine receptor |
3 |
|
chemokines, cc - genetics - metabolism |
3 |
|
chemotaxis - drug effects - physiology |
3 |
|
chemotaxis, leukocyte |
3 |
|
china - ethnology |
3 |
|
chinese subjects |
3 |
|
chlorambucil - therapeutic use |
3 |
|
chromatography, affinity |
3 |
|
chronic renal failure (crf) |
3 |
|
clarithromycin - adverse effects - pharmacokinetics |
3 |
|
coculture techniques |
3 |
|
collagen type i - metabolism |
3 |
|
colonoscopy |
3 |
|
colonoscopy - adverse effects |
3 |
|
coloring agents |
3 |
|
combined antibiotic therapy |
3 |
|
commencement |
3 |
|
complement c3 - biosynthesis - genetics |
3 |
|
complications |
3 |
|
continuous ambulatory peritoneal dialysis (capd) |
3 |
|
cross-talk |
3 |
|
culture media, conditioned - metabolism |
3 |
|
culture media, conditioned - metabolism - pharmacology |
3 |
|
cyclophosphamide - therapeutic use |
3 |
|
cyclosporins |
3 |
|
cytokines |
3 |
|
db/db mice |
3 |
|
delusions - chemically induced |
3 |
|
denver shunt |
3 |
|
diabetes mellitus, experimental - physiopathology |
3 |
|
diabetes mellitus, type 2 - complications |
3 |
|
diabetes mellitus, type 2 - complications - ethnology - genetics |
3 |
|
diabetic kidney disease |
3 |
|
diabetic nephropathies - ethnology - etiology - genetics |
3 |
|
diabetic nephropathies - etiology |
3 |
|
diabetic nephropathies - etiology - physiopathology |
3 |
|
diabetic nephropathies - metabolism - pathology |
3 |
|
diabetic nephropathies - metabolism - pathology - prevention and control |
3 |
|
dialysis solutions - adverse effects |
3 |
|
dialysis solutions - chemistry |
3 |
|
dialysis solutions - pharmacology |
3 |
|
diverticulosis |
3 |
|
diverticulosis, colonic - complications |
3 |
|
dna, complementary - analysis |
3 |
|
dna, viral - analysis |
3 |
|
dna, viral - genetics - isolation & purification |
3 |
|
down-regulation |
3 |
|
doxorubicin - adverse effects |
3 |
|
drug interactions |
3 |
|
drug resistance |
3 |
|
drug resistance, microbial |
3 |
|
drugs, chinese herbal - pharmacology |
3 |
|
e coli |
3 |
|
early diagnosis |
3 |
|
emt |
3 |
|
enalapril - therapeutic use |
3 |
|
enos knockout mice |
3 |
|
enteric peritonitis |
3 |
|
enzyme activation |
3 |
|
enzyme inhibitors - pharmacology |
3 |
|
enzyme inhibitors - therapeutic use |
3 |
|
epithelial cells - cytology - drug effects |
3 |
|
epithelial cells - cytology - drug effects - metabolism |
3 |
|
epithelial cells - drug effects |
3 |
|
epithelial cells - drug effects - enzymology - pathology |
3 |
|
epithelial cells - drug effects - immunology - metabolism - pathology |
3 |
|
epithelial cells - immunology - pathology |
3 |
|
epithelial cells - pathology |
3 |
|
epithelium - metabolism - pathology |
3 |
|
escherichia coli - enzymology |
3 |
|
escherichia coli infections |
3 |
|
ethics |
3 |
|
ethics, medical |
3 |
|
ethnic groups |
3 |
|
evaluation studies as topic |
3 |
|
extended-spectrum beta-lactamase |
3 |
|
extracellular signal-regulated map kinases - physiology |
3 |
|
fabry disease - diagnosis |
3 |
|
family |
3 |
|
fatal outcome |
3 |
|
fibroblasts |
3 |
|
flow cytometry |
3 |
|
galactose - analysis |
3 |
|
galactose deficiency |
3 |
|
ganoderma |
3 |
|
gastric acid inhibitor |
3 |
|
gene expression - physiology |
3 |
|
gene expression regulation |
3 |
|
gene expression regulation - drug effects - physiology |
3 |
|
gene therapy |
3 |
|
genes, ras - drug effects |
3 |
|
genetic predisposition to disease |
3 |
|
genetic predisposition to disease - genetics |
3 |
|
glomerular mesangium - blood supply - immunology - pathology |
3 |
|
glomerular mesangium - cytology |
3 |
|
glomerular mesangium - cytology - metabolism |
3 |
|
glomerular mesangium - immunology - pathology - physiopathology |
3 |
|
glomerular mesangium - pathology |
3 |
|
glomerular mesangium - physiology |
3 |
|
glomerulonephritis - metabolism |
3 |
|
glomerulonephritis, iga |
3 |
|
glomerulonephritis, iga - blood - drug therapy - physiopathology |
3 |
|
glomerulonephritis, iga - chemically induced - drug therapy - metabolism - pathology |
3 |
|
glomerulonephritis, iga - complications - genetics - immunology |
3 |
|
glomerulonephritis, iga - drug therapy - immunology |
3 |
|
glomerulonephritis, iga - enzymology - pathology |
3 |
|
glomerulonephritis, iga - genetics - pathology - therapy |
3 |
|
glomerulonephritis, iga - immunology |
3 |
|
glomerulonephritis, iga - immunology - metabolism - physiopathology |
3 |
|
glomerulonephritis, iga - immunology - pathology - physiopathology |
3 |
|
glomerulonephritis, iga - pathology |
3 |
|
glomerulonephritis, membranous - drug therapy - ethnology - metabolism |
3 |
|
glomerulonephritis, membranous - pathology - prevention & control - virology |
3 |
|
glomerulosclerosis, focal segmental - drug therapy - metabolism - pathology |
3 |
|
glomerulotubular interaction |
3 |
|
glucocorticoids - therapeutic use |
3 |
|
glucose - analysis - metabolism |
3 |
|
glycated albumin |
3 |
|
glycosylation - drug effects |
3 |
|
glycosylation end products, advanced - metabolism |
3 |
|
glycosylation end products, advanced - physiology |
3 |
|
graft rejection - virology |
3 |
|
graft survival |
3 |
|
graft survival - physiology |
3 |
|
gram-negative bacterial infections - drug therapy - etiology |
3 |
|
granuloma - etiology |
3 |
|
haematuria |
3 |
|
helical ct angiography |
3 |
|
hematuria - etiology |
3 |
|
hemolysis |
3 |
|
hemoperitoneum - etiology |
3 |
|
hepacivirus - genetics |
3 |
|
hepatitis b - drug therapy |
3 |
|
hepatitis b virus - drug effects - genetics - isolation & purification |
3 |
|
hepatitis b, chronic - complications - drug therapy - pathology |
3 |
|
hepatitis c |
3 |
|
hepatitis c - drug therapy - etiology - virology |
3 |
|
hepatocytes - cytology - metabolism |
3 |
|
hong kong - ethnology |
3 |
|
hospital costs |
3 |
|
human mesangial cell |
3 |
|
human mesangial cells |
3 |
|
human peritoneal mesothelial cells |
3 |
|
hydrogen-ion concentration |
3 |
|
hydrothorax |
3 |
|
hydrothorax - etiology - therapy |
3 |
|
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology - therapeutic use |
3 |
|
hypertonic glucose |
3 |
|
hyponatremia |
3 |
|
iga |
3 |
|
il-1β |
3 |
|
imidazoles - pharmacology |
3 |
|
immunity, innate - drug effects |
3 |
|
immunoglobulin a |
3 |
|
immunoglobulin a - blood - chemistry - immunology |
3 |
|
immunoglobulin a - blood - immunology - pharmacology |
3 |
|
immunoglobulin a - blood - therapeutic use |
3 |
|
immunoglobulin a - chemistry - metabolism |
3 |
|
immunoglobulin a - classification - isolation & purification - metabolism |
3 |
|
immunoglobulin a - drug effects - immunology |
3 |
|
immunoglobulin a - metabolism - pharmacology |
3 |
|
immunoglobulin a - pharmacology |
3 |
|
immunoglobulin gamma-chains - immunology - metabolism |
3 |
|
immunoglobulin kappa-chains - immunology - metabolism |
3 |
|
immunohistochemistry |
3 |
|
immunologic factors - therapeutic use |
3 |
|
immunomodulation - drug effects |
3 |
|
inflammation |
3 |
|
inflammation - pathology |
3 |
|
inflammation mediators - metabolism |
3 |
|
injections, intraperitoneal |
3 |
|
intercellular adhesion molecule-1 - genetics - metabolism |
3 |
|
intercellular adhesion molecule-1 - physiology |
3 |
|
interferon |
3 |
|
interferon-alpha - administration & dosage - adverse effects - therapeutic use |
3 |
|
interleukin-1beta - metabolism |
3 |
|
interleukin-2 receptor alpha subunit - analysis |
3 |
|
interleukin-2 receptor alpha subunit - genetics - metabolism |
3 |
|
interleukin-6 |
3 |
|
interleukin-6 - biosynthesis |
3 |
|
interleukin-6 - biosynthesis - genetics |
3 |
|
interleukin-6 - genetics - metabolism |
3 |
|
interleukin-8 - genetics - metabolism |
3 |
|
interleukin-8 - metabolism |
3 |
|
ischemia |
3 |
|
kallikrein-kinin system - physiology |
3 |
|
kdigo |
3 |
|
kidney - blood supply |
3 |
|
kidney - cytology |
3 |
|
kidney - drug effects - immunology - metabolism - pathology |
3 |
|
kidney - physiology |
3 |
|
kidney - physiopathology |
3 |
|
kidney biopsy |
3 |
|
kidney diseases - virology |
3 |
|
kidney failure, chronic - complications |
3 |
|
kidney failure, chronic - diagnosis - therapy |
3 |
|
kidney failure, chronic - pathology - prevention & control - virology |
3 |
|
kidney failure, chronic - prevention & control |
3 |
|
kidney failure, chronic - surgery |
3 |
|
kidney glomerulus - blood supply - chemistry - immunology |
3 |
|
kidney glomerulus - metabolism |
3 |
|
kidney transplantation - adverse effects - immunology - mortality |
3 |
|
kidney transplantation - ethics - methods |
3 |
|
kidney transplantation - methods - physiology |
3 |
|
kidney transplantation - pathology |
3 |
|
kidney transplantation - physiology |
3 |
|
kidney tubules - cytology - metabolism - pathology |
3 |
|
kidney tubules, proximal - cytology - drug effects |
3 |
|
kidney tubules, proximal - drug effects - immunology - metabolism - pathology |
3 |
|
kidney tubules, proximal - drug effects - metabolism - pathology |
3 |
|
kidney tubules, proximal - immunology - pathology |
3 |
|
kidney tubules, proximal - pathology |
3 |
|
kidney tubules, proximal - physiology |
3 |
|
kim-1 |
3 |
|
kt/v |
3 |
|
lamivudine |
3 |
|
lamivudine - administration & dosage |
3 |
|
lamivudine - therapeutic use |
3 |
|
leukocytes - immunology - metabolism |
3 |
|
leukocytes, mononuclear - immunology |
3 |
|
lingzhi |
3 |
|
lipocalins - genetics - immunology - metabolism |
3 |
|
liver - enzymology |
3 |
|
liver cirrhosis - complications |
3 |
|
liver neoplasms - diagnosis - pathology |
3 |
|
liver transplantation - methods - physiology |
3 |
|
living donors - ethics - supply & distribution |
3 |
|
living renal donors |
3 |
|
living-related donor |
3 |
|
longitudinal studies |
3 |
|
losartan - administration & dosage |
3 |
|
losartan - pharmacology |
3 |
|
losartan - pharmacology - therapeutic use |
3 |
|
losartan - therapeutic use |
3 |
|
low-gdp dialysate |
3 |
|
lung abscess |
3 |
|
lung abscess - microbiology - radiography |
3 |
|
lymphocele |
3 |
|
lymphoproliferative disorders - etiology |
3 |
|
macromolecular iga1 |
3 |
|
macrophage migration inhibitory factor |
3 |
|
macrophage migration-inhibitory factors - genetics |
3 |
|
macrophage migration-inhibitory factors - immunology |
3 |
|
macrophage migration-inhibitory factors - physiology |
3 |
|
macrophages - drug effects |
3 |
|
mannitol |
3 |
|
map kinase signaling system |
3 |
|
mapk |
3 |
|
membrane proteins - biosynthesis - genetics |
3 |
|
mesangial binding |
3 |
|
mesangial cells |
3 |
|
mesangial cells - cytology |
3 |
|
mesangial cells - cytology - drug effects - metabolism |
3 |
|
mesangial cells - immunology - pathology |
3 |
|
mesangial cells - metabolism - pathology |
3 |
|
mesothelial cells |
3 |
|
mesothelium |
3 |
|
mice, inbred balb c |
3 |
|
microrna |
3 |
|
minimal |
3 |
|
minimal change disease |
3 |
|
mitogen-activated protein kinase 1 - metabolism |
3 |
|
mitogen-activated protein kinase 3 - metabolism |
3 |
|
models, biological |
3 |
|
molecular weight |
3 |
|
monocytes |
3 |
|
monocytes - cytology - metabolism |
3 |
|
monocytes - pathology - physiology |
3 |
|
morbidity |
3 |
|
multiple renal arteries |
3 |
|
multiplex igan family |
3 |
|
mutation |
3 |
|
mycobacterium tuberculosis - drug effects - isolation & purification |
3 |
|
n-acetylneuraminic acid - analysis |
3 |
|
nephrectomy |
3 |
|
nephritis, interstitial - immunology - metabolism - pathology - prevention and control |
3 |
|
neuraminidase - pharmacology |
3 |
|
neutrophils |
3 |
|
neutrophils - immunology - metabolism - pathology |
3 |
|
ngal |
3 |
|
onychomycosis - etiology |
3 |
|
optimal |
3 |
|
organ preservation |
3 |
|
osteonecrosis - diagnosis - epidemiology - etiology |
3 |
|
oxidative stress |
3 |
|
oxidative stress - drug effects - physiology |
3 |
|
par-1 |
3 |
|
particle size |
3 |
|
pathogenesis |
3 |
|
penicillanic acid - analogs & derivatives - therapeutic use |
3 |
|
penicillins - therapeutic use |
3 |
|
peptidyl-dipeptidase a - metabolism |
3 |
|
peritoneal defence |
3 |
|
peritoneal dialysis - mortality |
3 |
|
peritoneal dialysis, continuous ambulatory - adverse effects - methods |
3 |
|
peritoneum - metabolism - pathology |
3 |
|
peritoneum - physiopathology |
3 |
|
peritonitis - diagnosis - etiology - metabolism - pathology |
3 |
|
peritonitis - drug therapy - epidemiology - prevention & control |
3 |
|
peritonitis - epidemiology - etiology |
3 |
|
peritonitis - metabolism - pathology |
3 |
|
peritonitis - microbiology |
3 |
|
peritonitis - pathology |
3 |
|
peritonitis, tuberculous - complications - drug therapy - mortality |
3 |
|
peroxisome proliferator-activated receptor-γ |
3 |
|
peroxisome proliferator-activated receptor-γ agonist |
3 |
|
ph |
3 |
|
phenotype |
3 |
|
piperacillin - therapeutic use |
3 |
|
plasma renin activity |
3 |
|
pleurodesis |
3 |
|
pleurodesis - methods |
3 |
|
podocyte |
3 |
|
podocytes - metabolism |
3 |
|
poly(adp-ribose) polymerases - biosynthesis |
3 |
|
polymorphism, genetic |
3 |
|
polymorphism, single nucleotide - genetics |
3 |
|
postoperative complications - epidemiology |
3 |
|
postoperative complications - therapy |
3 |
|
postrenal transplant |
3 |
|
ppar gamma - agonists |
3 |
|
ppar gamma - agonists - physiology |
3 |
|
ppar gamma - metabolism |
3 |
|
ppar-g agonist |
3 |
|
ppar-γ |
3 |
|
pregnancy |
3 |
|
pregnancy proteins - metabolism |
3 |
|
probability |
3 |
|
protective agents - pharmacology |
3 |
|
protein binding |
3 |
|
protein processing, post-translational - drug effects |
3 |
|
proteinuria - metabolism |
3 |
|
proteinuria - pathology - physiopathology |
3 |
|
proteinuric nephropathy |
3 |
|
proto-oncogene proteins - genetics - immunology - metabolism |
3 |
|
proximal tubular cells |
3 |
|
proximal tubular epithelial cell |
3 |
|
proximal tubular epithelial cells |
3 |
|
proximal tubule |
3 |
|
psychological symptoms |
3 |
|
pyridines - pharmacology |
3 |
|
ramipril - therapeutic use |
3 |
|
receptor, angiotensin, type 1 - genetics - metabolism |
3 |
|
receptor, angiotensin, type 1 - genetics - metabolism - physiology |
3 |
|
receptor, angiotensin, type 1 - metabolism |
3 |
|
receptor, angiotensin, type 2 - biosynthesis - metabolism |
3 |
|
receptor, angiotensin, type 2 - genetics - metabolism |
3 |
|
receptor, angiotensin, type 2 - physiology |
3 |
|
receptors, bradykinin - physiology |
3 |
|
receptors, chemokine - genetics - metabolism |
3 |
|
receptors, fc - analysis |
3 |
|
recombinant proteins |
3 |
|
recombinant proteins - chemistry |
3 |
|
recombinant proteins - therapeutic use |
3 |
|
reference values |
3 |
|
renal arteriography |
3 |
|
renal artery - abnormalities - radiography |
3 |
|
renal artery - radiography |
3 |
|
renal artery obstruction - diagnosis - epidemiology - therapy |
3 |
|
renal biopsy |
3 |
|
renal fibrosis |
3 |
|
renal inflammation |
3 |
|
renal medicine |
3 |
|
renal pathology |
3 |
|
renal replacement therapy |
3 |
|
renal survival |
3 |
|
renal tubular cell |
3 |
|
renal tubular epithelial cells |
3 |
|
renin - genetics |
3 |
|
renin-angiotensin system |
3 |
|
renin-angiotensin system - genetics - physiology |
3 |
|
renin-angiotensin system - physiology |
3 |
|
reverse transcriptase inhibitors - administration & dosage |
3 |
|
rhodococcus equi |
3 |
|
rhodococcus equi - isolation & purification |
3 |
|
ribavirin |
3 |
|
ribavirin - administration & dosage - adverse effects - therapeutic use |
3 |
|
rifampin - therapeutic use |
3 |
|
risk assessment |
3 |
|
rna, messenger - analysis |
3 |
|
rna, messenger - metabolism |
3 |
|
rupture, spontaneous |
3 |
|
sampling studies |
3 |
|
sciatica - etiology |
3 |
|
screening |
3 |
|
sensitivity and specificity |
3 |
|
serum |
3 |
|
serum cytokines |
3 |
|
sex distribution |
3 |
|
shear wave elastography |
3 |
|
shock - etiology |
3 |
|
signal transduction |
3 |
|
signal transduction - drug effects |
3 |
|
signaling |
3 |
|
sirolimus - therapeutic use |
3 |
|
sleep |
3 |
|
sleep apnea syndromes - complications - epidemiology - therapy |
3 |
|
smad proteins - metabolism |
3 |
|
smad6 |
3 |
|
smad7 |
3 |
|
spleen tyrosine kinase |
3 |
|
spousal donor |
3 |
|
spouses |
3 |
|
stat1 transcription factor - metabolism |
3 |
|
streptococcal infections - etiology - immunology - metabolism |
3 |
|
streptococcus |
3 |
|
streptozotocin |
3 |
|
survival analysis |
3 |
|
t cells |
3 |
|
t-lymphocytes - pathology - physiology |
3 |
|
talc |
3 |
|
talc poudrage |
3 |
|
target |
3 |
|
terfenadine - adverse effects |
3 |
|
tgf-beta |
3 |
|
thiazolidinediones - pharmacology |
3 |
|
thiazolidinediones - pharmacology - therapeutic use |
3 |
|
thienamycins - therapeutic use |
3 |
|
thoracoscopy - methods |
3 |
|
tinea - etiology |
3 |
|
tinea pedis - etiology |
3 |
|
tissue and organ harvesting |
3 |
|
tissue and organ procurement - organization & administration |
3 |
|
toll-like receptor 4 |
3 |
|
toll-like receptors - physiology |
3 |
|
tomography, x-ray computed - economics - methods |
3 |
|
transcription factors - metabolism |
3 |
|
transferrin - metabolism - pharmacology |
3 |
|
transforming growth factor beta - biosynthesis - drug effects |
3 |
|
transforming growth factor beta - biosynthesis - genetics - metabolism |
3 |
|
transforming growth factor beta - biosynthesis - genetics - physiology |
3 |
|
transforming growth factor beta - metabolism |
3 |
|
transforming growth factor beta1 |
3 |
|
transplantation |
3 |
|
transplantation immunology |
3 |
|
transplantation, homologous - immunology - mortality |
3 |
|
treatment |
3 |
|
treatment, infectious peritonitis |
3 |
|
trypan blue |
3 |
|
tuberculosis |
3 |
|
tuberculosis - complications - drug therapy - mortality |
3 |
|
tuberculosis - diagnosis - drug therapy - epidemiology - etiology |
3 |
|
tuberculosis, lymph node - complications - drug therapy - mortality |
3 |
|
tuberculosis, pulmonary - complications - drug therapy - mortality |
3 |
|
tuberculous peritonitis |
3 |
|
tubular |
3 |
|
tubular atrophy |
3 |
|
tubular epithelial cells |
3 |
|
tubulointerstitial disease |
3 |
|
tubulointerstitial pathology |
3 |
|
tumor cells, cultured |
3 |
|
tumor necrosis factor-alpha - biosynthesis - drug effects |
3 |
|
tumor necrosis factor-alpha - genetics - therapeutic use |
3 |
|
tumor necrosis factor-alpha - physiology |
3 |
|
u937 cells |
3 |
|
ultrafiltration |
3 |
|
ultrasonography |
3 |
|
ultrasound |
3 |
|
uninephrectomy |
3 |
|
up-regulation - physiology |
3 |
|
urothelium - metabolism |
3 |
|
vancomycin - therapeutic use |
3 |
|
vasculitis - immunology |
3 |
|
video recording |
3 |
|
vimentin - metabolism |
3 |
|
wnt/β-catenin |
3 |
|
aanti-gbm |
2 |
|
aav |
2 |
|
abdomen - ultrasonography |
2 |
|
aliskiren |
2 |
|
allergen |
2 |
|
amyloidosis - diagnosis - etiology - physiopathology - therapy |
2 |
|
anc |
2 |
|
anca |
2 |
|
anoxia - complications - diagnosis - physiopathology |
2 |
|
anti-arrhythmia agents - adverse effects |
2 |
|
anti-fibrotic |
2 |
|
anti-gbm |
2 |
|
anti-glomerular basement membrane disease - complications - diagnosis |
2 |
|
antibodies, antinuclear - blood |
2 |
|
anticoagulants (medicine) |
2 |
|
antigen presentation |
2 |
|
antilymphocyte serum - adverse effects - therapeutic use |
2 |
|
antithrombin iii |
2 |
|
antitubercular agents - administration & dosage |
2 |
|
antiviral agents - pharmacology - therapeutic use |
2 |
|
antiviral agents - therapeutic use |
2 |
|
arteriovenous fistula/radiography |
2 |
|
arteriovenous fistula/therapy |
2 |
|
autoantibodies - immunology |
2 |
|
autoantibody |
2 |
|
autoantigens - immunology |
2 |
|
automated peritoneal dialysis |
2 |
|
beta 2-microglobulin - physiology |
2 |
|
biopsy, needle |
2 |
|
bk virus-associated nephropathy |
2 |
|
blood glucose - analysis |
2 |
|
body fluids - physiology |
2 |
|
brain neoplasms - etiology - radiography - virology |
2 |
|
c3 |
2 |
|
calcineurine inhibitor |
2 |
|
catheterization, central venous - methods |
2 |
|
catheters, indwelling - adverse effects |
2 |
|
central venous catheter |
2 |
|
chronic hepatitis |
2 |
|
cohort |
2 |
|
cohort study |
2 |
|
combined modality therapy |
2 |
|
complement system proteins - biosynthesis - physiology |
2 |
|
confusion - etiology |
2 |
|
consensus statements |
2 |
|
cyclophosphamide - administration & dosage - therapeutic use |
2 |
|
cystitis - complications - diagnosis |
2 |
|
cytomegalovirus retinitis - drug therapy - etiology |
2 |
|
delirium |
2 |
|
diabetic nephropathies |
2 |
|
disease progression |
2 |
|
dna - immunology |
2 |
|
drug evaluation |
2 |
|
drug resistance, viral |
2 |
|
egfr |
2 |
|
emphysema - complications - diagnosis |
2 |
|
emphysema - microbiology - radiography |
2 |
|
end-stage renal disease |
2 |
|
end-stage renal failure |
2 |
|
endosonography |
2 |
|
eosinophilia - drug therapy - etiology |
2 |
|
eosinophilic peritonitis |
2 |
|
epithelial cells. |
2 |
|
epstein-barr virus infections - complications - diagnosis |
2 |
|
erythrocyte transfusion - methods |
2 |
|
ethnic difference |
2 |
|
exercise capacity |
2 |
|
exercise test - statistics & numerical data |
2 |
|
exercise therapy - statistics & numerical data |
2 |
|
exercise training |
2 |
|
famotidine |
2 |
|
fluoroscopy |
2 |
|
ganciclovir - therapeutic use |
2 |
|
gastrointestinal hemorrhage - complications - diagnosis |
2 |
|
gene polymorphism association |
2 |
|
glomerulonephritis, iga - immunology - metabolism |
2 |
|
glomerulonephritis, membranous - drug therapy - virology |
2 |
|
glomerulosclerosis, focal segmental - drug therapy - pathology |
2 |
|
glucagon-like peptide-1 receptor agonist |
2 |
|
graft rejection - drug therapy |
2 |
|
h2 receptor antagonists |
2 |
|
hemangioma, cavernous - complications - congenital |
2 |
|
hemolytic-uremic syndrome - complications - diagnosis |
2 |
|
hepatitis b - congenital - drug therapy |
2 |
|
hepatitis b virus |
2 |
|
hepatitis, viral, human - epidemiology - etiology - prevention & control - therapy |
2 |
|
hernia, abdominal - diagnosis - etiology - therapy |
2 |
|
herpesvirus 4, human - isolation & purification |
2 |
|
histamine h1 antagonists - therapeutic use |
2 |
|
histological staging |
2 |
|
hydrothorax - diagnosis - etiology - therapy |
2 |
|
hypoalbuminemia - drug therapy - etiology |
2 |
|
incidence |
2 |
|
infection control |
2 |
|
insulin resistance |
2 |
|
internal thoracic vein |
2 |
|
isn |
2 |
|
kallikrein-kinin system |
2 |
|
ketotifen |
2 |
|
ketotifen - therapeutic use |
2 |
|
kidney - microbiology - radiography |
2 |
|
kidney diseases - chemically induced |
2 |
|
kidney diseases - radiography |
2 |
|
kidney failure, chronic - complications - psychology - therapy |
2 |
|
kidney failure, chronic - etiology |
2 |
|
kidney neoplasms - etiology - radiography - virology |
2 |
|
kidney transplant |
2 |
|
kidney tubules - ultrastructure |
2 |
|
kidney tubules. |
2 |
|
kidneys - cytology. |
2 |
|
kidneys - diseases. |
2 |
|
kidneys. |
2 |
|
klebsiella infections - radiography |
2 |
|
klebsiella pneumoniae |
2 |
|
lamivudine - pharmacology - therapeutic use |
2 |
|
lipids - blood |
2 |
|
liver transplantation |
2 |
|
local synthesis |
2 |
|
lupus nephritis - blood - classification - complications - drug therapy - pathology |
2 |
|
lupus nephritis - drug therapy - pathology |
2 |
|
lupus nephritis - etiology - immunology - metabolism |
2 |
|
lymphocele - diagnosis - etiology - therapy |
2 |
|
lymphoma, large b-cell, diffuse - etiology - radiography - virology |
2 |
|
meta-analysis |
2 |
|
method |
2 |
|
microscopy, electron |
2 |
|
monitoring, physiologic |
2 |
|
muromonab-cd3 - adverse effects - therapeutic use |
2 |
|
n-acetyl-seryl-aspartyl-lysyl-proline |
2 |
|
nephritis, interstitial - etiology - metabolism - physiopathology |
2 |
|
nitric oxide |
2 |
|
nocturnal myoclonus syndrome - etiology |
2 |
|
non-steroidal mineralocorti-coid receptor antagonist |
2 |
|
nondiabetic ckd |
2 |
|
nucleosome |
2 |
|
obesity |
2 |
|
periodicity |
2 |
|
peritoneal dialysis - psychology |
2 |
|
peritoneal dialysis, continuous ambulatory - statistics & numerical data |
2 |
|
peritoneal eosinophilia |
2 |
|
peritoneum - physiology |
2 |
|
peritonitis - drug therapy - etiology |
2 |
|
peritonitis, tuberculous - drug therapy - epidemiology - etiology |
2 |
|
phlebography |
2 |
|
physical rehabilitation |
2 |
|
pilot projects |
2 |
|
podocytopathy |
2 |
|
postoperative complications - etiology - pathology - virology |
2 |
|
posture |
2 |
|
prednisone - therapeutic use |
2 |
|
prevention |
2 |
|
prodrugs - therapeutic use |
2 |
|
progression genes |
2 |
|
proliferative lupus nephritis |
2 |
|
proteasome endopeptidase complex - genetics - immunology - metabolism |
2 |
|
protein c |
2 |
|
protein s |
2 |
|
proteins - synthesis. |
2 |
|
proteinuria - complications - physiopathology |
2 |
|
pulmonary gas exchange |
2 |
|
purpura, thrombotic thrombocytopenic - complications - diagnosis |
2 |
|
pyelonephritis - microbiology - radiography |
2 |
|
questionnaire |
2 |
|
questionnaires |
2 |
|
radiography, abdominal |
2 |
|
receptors, immunologic - metabolism |
2 |
|
recurrence |
2 |
|
recurrence - prevention & control |
2 |
|
remission induction |
2 |
|
renal dialysis - adverse effects |
2 |
|
renal dialysis - methods |
2 |
|
renal disease |
2 |
|
renoprotection |
2 |
|
restless legs |
2 |
|
risk factor |
2 |
|
risk prediction |
2 |
|
rna, viral - isolation & purification |
2 |
|
safety |
2 |
|
saturated fatty acids |
2 |
|
selective endothelin receptor antagonist |
2 |
|
sglt2 inhibitor |
2 |
|
sleep apnea syndromes - complications |
2 |
|
sleep apnea syndromes - complications - diagnosis |
2 |
|
sleep apnea syndromes - etiology |
2 |
|
sleep disorders - complications |
2 |
|
sleep disorders - etiology |
2 |
|
sodium-glucose transporter 2 inhibitors |
2 |
|
sotalol - adverse effects |
2 |
|
southeast asia |
2 |
|
statistics, nonparametric |
2 |
|
stents |
2 |
|
steroid-resistance |
2 |
|
superoxide |
2 |
|
superoxides - metabolism |
2 |
|
susceptibility genes |
2 |
|
thrombosis |
2 |
|
tlr4 ko mice |
2 |
|
toll-like receptor |
2 |
|
torsades de pointes - chemically induced |
2 |
|
transplantation, autologous |
2 |
|
transplantation, homologous - pathology |
2 |
|
ubiquitin - metabolism |
2 |
|
unilateral ureteric obstruction |
2 |
|
urine cytology |
2 |
|
vascular age |
2 |
|
veins - ultrasonography |
2 |
|
venography |
2 |
|
viral hepatitis vaccines - therapeutic use |
2 |
|
water-electrolyte imbalance - complications |
2 |
|
2019-ncov |
1 |
|
ace inhibitor |
1 |
|
acetyl-coenzyme a carboxylase beta |
1 |
|
actinomycetales infections - drug therapy - etiology |
1 |
|
actinomycetales infections - etiology |
1 |
|
administration, oral |
1 |
|
analgesics |
1 |
|
anorexia |
1 |
|
anti-bacterial agents - administration & dosage |
1 |
|
anti-gbm crescentic glomerulonephritis |
1 |
|
anti-inflammatory agents - therapeutic use |
1 |
|
antibodies, monoclonal - blood |
1 |
|
asia |
1 |
|
asian |
1 |
|
atp |
1 |
|
atrasentan |
1 |
|
av fistula |
1 |
|
bio-sensing |
1 |
|
blotting, western |
1 |
|
brain stem infarctions - diagnosis |
1 |
|
brunei |
1 |
|
cambodia |
1 |
|
cancer |
1 |
|
cancer-associated fibroblast |
1 |
|
carcinoma, hepatocellular - diagnosis - secondary |
1 |
|
cardiovascular |
1 |
|
cell adhesion |
1 |
|
child |
1 |
|
chronic kidney failure |
1 |
|
complement c3 - immunology - metabolism - secretion |
1 |
|
connexin |
1 |
|
connexins |
1 |
|
coronavirus disease 2019 |
1 |
|
creatinine |
1 |
|
cyclosporine - adverse effects |
1 |
|
cystatin c |
1 |
|
data collection |
1 |
|
device removal |
1 |
|
diabetes mellitus, type 2 - complications - epidemiology |
1 |
|
diabetic nephropathies - complications - epidemiology - physiopathology |
1 |
|
dna mutational analysis |
1 |
|
drug eruptions - etiology |
1 |
|
end-stage renal disease (esrd) |
1 |
|
endophthalmitis - microbiology - physiopathology - surgery |
1 |
|
endothelin receptor antagonist |
1 |
|
epithelial cells - metabolism |
1 |
|
everolimus |
1 |
|
first-degree relatives |
1 |
|
flushing - chemically induced |
1 |
|
gastric motility |
1 |
|
gene amplification |
1 |
|
geographical differences |
1 |
|
glycosuria |
1 |
|
guideline |
1 |
|
health care policy |
1 |
|
health policy |
1 |
|
hematuria |
1 |
|
hemichannels |
1 |
|
immunocompromised host |
1 |
|
innate immunity |
1 |
|
interventional nephrology (in) |
1 |
|
kidney - secretion |
1 |
|
kidney disease |
1 |
|
kidney diseases |
1 |
|
kidney failure, chronic - epidemiology - etiology - prevention & control |
1 |
|
kidney failure, chronic - immunology - therapy |
1 |
|
kidney transplantation - immunology |
1 |
|
kidney tubules, proximal - drug effects - metabolism |
1 |
|
klebsiella infections - physiopathology - surgery |
1 |
|
klebsiella pneumoniae - isolation & purification - pathogenicity |
1 |
|
left ventricular hypertrophy |
1 |
|
liver |
1 |
|
long non-coding rna |
1 |
|
low-to-middle income countries |
1 |
|
lung neoplasms - secondary |
1 |
|
lymphoma |
1 |
|
macrophages |
1 |
|
medical audit |
1 |
|
mtor |
1 |
|
mycobacterium fortuitum - drug effects |
1 |
|
mycobacterium infections, nontuberculous - drug therapy |
1 |
|
myeloid-tlr4 |
1 |
|
nephrologists |
1 |
|
nephrosis, lipoid - drug therapy |
1 |
|
nonsteroidal anti-inflammatory drug |
1 |
|
north and east asia |
1 |
|
nr4a1/ear2 |
1 |
|
onconephrology |
1 |
|
opioids |
1 |
|
pain |
1 |
|
peritonitis - microbiology - therapy |
1 |
|
permeability |
1 |
|
personalized medicine |
1 |
|
philippines |
1 |
|
posttransplant lymphoproliferative disorders |
1 |
|
primary health care |
1 |
|
pro-fibrotic |
1 |
|
proinflammatory |
1 |
|
proteinuria - complications |
1 |
|
radionuclide techniques |
1 |
|
randomized trial |
1 |
|
registries |
1 |
|
registry |
1 |
|
renal cell carcinoma |
1 |
|
renal dialysis |
1 |
|
rhodococcus - isolation & purification |
1 |
|
rhodococcus equi - drug effects |
1 |
|
rhodococcus peritonitis |
1 |
|
sirolimus |
1 |
|
smad3 |
1 |
|
south-east asia |
1 |
|
steroids - therapeutic use |
1 |
|
thailand |
1 |
|
toll-like receptors |
1 |
|
tunneled catheter |
1 |
|
type 2 diabetes |
1 |
|
unconsciousness - etiology |
1 |
|
unilateral ureteral obstruction |
1 |
|
vascular access |
1 |
|
vascular access surveillance |
1 |
|
vitrectomy |
1 |
|
world health |
1 |
